Gene Type Associated with Higher Risk of Celiac Disease
|
By LabMedica International staff writers Posted on 10 Jul 2014 |
Researcher have found that children born with 2 copies of a high-risk variant in a specific group of genes confers 26% chance of developing celiac disease autoimmunity (CDA), an early sign of celiac disease (CD), by age 5. They also found a higher celiac risk in Sweden than in the three other studied countries, even with the same genetic risk factors.
The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.
“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).
Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.
Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.
The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.
The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.
Related Links:
National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease
The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.
“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).
Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.
Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.
The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.
The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.
Related Links:
National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease
Latest Molecular Diagnostics News
- Simple One-Hour Saliva Test Detects Common Cancers
- Blood Test Could Help Guide Treatment Decisions in Germ Cell Tumors
- Blood Test Could Spot Common Post-Surgery Condition Early
- New Blood Test Can Help Predict Testicular Cancer Recurrence
- New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
- New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
- Cell-Free DNA Predicts Bloodstream Infections in Children with Leukemia
- Study Uses Blood Samples to Identify Diseases Years Before They Start
- MicroRNA-Based Method Predicts CKD and Cardiovascular Risk
- Swab Test Helps Transplant Patients Receive Right Anti-Rejection Medication Dose
- Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
- Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
- Blood Test Could Help Detect Gallbladder Cancer Earlier
- New Blood Test Score Detects Hidden Alcohol-Related Liver Disease
- New Blood Test Predicts Who Will Most Likely Live Longer
- Genetic Test Predicts Radiation Therapy Risk for Prostate Cancer Patients
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read more
World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
Blood sampling is one of the most common clinical procedures, but it can be difficult or uncomfortable for many patients, especially older adults or individuals with certain medical conditions.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







